UChicago Medicine


27th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium

presented by UChicago Medicine

3 others would like to attend.

Register Now

Notification icon Friday, May 10, 2024 8:15 AM - 3:40 PM America/Los_Angeles

Event info


The goals of this activity are to help participants examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rational for and results of studies that include novel agents for the treatment of patients with advanced cancer. This knowledge will enable them to appropriately utilize new treatments available to cancer patients, provide support for current and future oncology clinical trials, and become stronger leaders in the area of oncology research. In sum, this program will convey information on how to better implement precision medicine in oncologic care, leading to better outcomes for patients suffering from cancer.


This activity has been designed for physicians and other healthcare professionals currently involved in the diagnosis, screening, and treatment of cancer patients.



At the conclusion of this activity, participants will be able to:

  • Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;

  • State the clinical effects of novel immunotherapeutic agents, including but not limited to novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;

  • Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;

  • Describe the current science related to radioligand therapy and available agents;

  • Discuss advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.

  • Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors.


The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.

  • Olatoyosi Odenike

    Course Director

  • Walter M. Stadler

    Course Director

3 others would like to attend.

Register Now

Login to view comments. Click here to Login